NeuroServo

NeuroServo operates at the intersection of medical devices, digital health, intensive-care monitoring, and neuroscience. Its core differentiation is the attempt to make EEG assessment faster and easier to deploy in emergency and intensive-care environments. VEEGix is described as a miniaturized prefrontal EEG that nurses can install, with an interpretable brain status available within about a minute, compared with the longer workflows associated with conventional EEG technician setup and neurologist interpretation. The product is positioned as an emergency triage and monitoring tool rather than a replacement for full diagnostic EEG, which gives the company a focused clinical use case. That limits direct benchmarking. Its small employee range, approximately $2.52 million in recorded funding, and seed-stage status suggest an early commercial position rather than a scaled category leader.

NeuroServo’s trajectory shows a long product-development cycle followed by a meaningful financing step in 2023. Founded in 2015, the company raised $22,016 in recorded non-equity assistance in 2019, followed by approximately $762,978 in pre-seed funding on Feb 1, 2020. Its 2021 milestones were primarily product and team oriented: VEEGix received a Health Canada Medical Device License on Oct 12, 2021, and François Marquis joined as Chief Medical Officer on Oct 26, 2021. A further Seed round was recorded on Aug 1, 2022, although its amount is undisclosed. The major financial inflection point came on Jun 20, 2023, when NeuroServo closed approximately $1.74 million in USD equivalent from a C$2.3 million Seed round led by three Quebec institutions. That financing followed grant and non-equity assistance activity in April 2023 and likely supported continued product development, clinical adoption, and commercialization. However, the company remains in the 1–10 employee range, with no documented hiring momentum and no disclosed financing after June 2023. The evidence therefore supports steady validation and incremental financing, but not yet a demonstrable scale-up phase.